Objective: Tranylcypromine has been recommend as an option for therapy-resistant depressive and anxiety disorders. In this case report the effectiveness of this medication as a part of a combined therapy-program including pharmacological, behavioural and psychodynamic interventions could be demonstrated on an outpatient with a therapy-resistant depression and agoraphobia.
Methods: The development of the illness, clinical symptoms and the 4 year ongoing therapy of a 69-year old patient are described in detail.
Results/conclusion: After the failure of 13 antidepressant agents with considerable side effects, a one year sustained remission of depression as well as great improvement of agoraphobia could be achieved with tranylcypromine. In this situation, tranylcypromine showed itself, for the first time, to be a very effective and well tolerated antidepressant.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0030-1248499 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasma Concentrations of Tranylcypromine in Depressed Patients With Chronic Kidney Disease: Two Case Reports.
J Clin Psychopharmacol
April 2024
Analytical Clinical Concepts (ACC), Leidersbach, Germany.
Purpose: The prevalence of comorbid depression and chronic kidney disease (CKD) is high. The aim of this brief report was to review 2 cases of treatment with tranylcypromine (TCP) in patients with treatment-resistant depression (TRD) and CKD. Tests of the plasma concentration of TCP were included.
View Article and Find Full Text PDFTreatment of Status Epilepticus after Traumatic Brain Injury Using an Antiseizure Drug Combined with a Tissue Recovery Enhancer Revealed by Systems Biology.
Int J Mol Sci
September 2023
A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.
Article Synopsis
- A study tested compounds discovered through bioinformatics that target molecular dysregulation caused by traumatic brain injury (TBI) to improve recovery and enhance antiseizure treatment.
- Five compounds were identified, with trichostatin A (TSA) showing the strongest neuroprotective, antioxidative, and anti-inflammatory effects in laboratory experiments.
- In a rat model study, TSA combined with the antiseizure drug levetiracetam (LEV) showed some benefits in reducing seizures but didn't clearly outperform LEV alone; further research is needed to assess long-term outcomes.
Design, synthesis and in vitro/in vivo anticancer activity of tranylcypromine-based triazolopyrimidine analogs as novel LSD1 inhibitors.
Eur J Med Chem
May 2023
Henan Engineering Research Center for Prevention and Treatment of Major Chronic Diseases with Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou, 450046, China; Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, 450046, China. Electronic address:
Histone lysine specific demethylase 1 (LSD1) is responsible for the demethylation of mono-/dimethylated lysine residue on histone proteins. LSD1 plays an extensive and essential role in the pathogenesis and progression of many human diseases such as cancers, and thus is becoming an attractive therapeutic target for cancer treatment. Tranylcypromine (TCP) is an important chemical template for developing irreversible LSD1 inhibitors, representing a major chemotype of clinical candidates.
View Article and Find Full Text PDFChronic SSRI Treatment, but Not Norepinephrine Reuptake Inhibitor Treatment, Increases Neurogenesis in Juvenile Rats.
Int J Mol Sci
June 2022
Kirksville College of Osteopathic Medicine, A.T. Still University, Kirksville, MO 63501, USA.
There has been growing recognition that major depressive disorder is a serious medical disorder that also affects children. This has been accompanied by an increased use of antidepressant drugs in adolescents; however, not all classes of antidepressants are effective in children and adolescents. There is an increasing need to understand the differences in antidepressant action in different developmental stages.
View Article and Find Full Text PDFHeterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity.
J Enzyme Inhib Med Chem
December 2022
Department of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy. Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti.
As regioisomers/bioisosteres of , a 4-phenylbenzamide tranylcypromine (TCP) derivative previously disclosed by us, we report here the synthesis and biological evaluation of some (hetero)arylbenzoylamino TCP derivatives -, in which the 4-phenyl moiety of was shifted at the benzamide C3 position or replaced by 2- or 3-furyl, 2- or 3-thienyl, or 4-pyridyl group, all at the benzamide C4 or C3 position. In anti-LSD1-CoREST assay, all the derivatives were more effective than the analogues, with the thienyl analogs and being the most potent (IC values = 0.015 and 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!